Cassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development Needed
Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...
STAT6d
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava Sciences, Inc. (SAVA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
thedeepdive6d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails
Cassava Sciences stock collapsed after an Alzheimer’s drug the company was testing failed to significantly help participants ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...
GlobalData on MSN6d
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.
BioSpace6d
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...
Yahoo6d
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Roche's Proposed ...
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
FY2024 EPS Estimate for Cassava Sciences Reduced by Analyst
Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...